Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 10, 2013, Pages 2203-2209

  Alteri, Claudia ^a   Artese, Anna ^b   Beheydt, Gertjan ^c   Santoro, Maria Mercedes ^a   Costa, Giosué ^b   Parrotta, Lucia ^b   Bertoli, Ada ^d   Gori, Caterina ^e   Orchi, Nicoletta ^e   Girardi, Enrico ^e   Antinori, Andrea ^e   Alcaro, Stefano ^b   Monforte, Antonella D'Arminio ^f   Theys, Kristof ^c   Vandamme, Anne Mieke ^c,g   Ceccherini Silberstein, Francesca ^a   Svicher, Valentina ^a   Perno, Carlo Federico ^a,d,e  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^d TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^e NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^f SAN PAOLO HOSPITAL   (Italy)

^g INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

Author keywords

Antiviral; Drug resistance; Molecular modelling

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; LOPINAVIR PLUS RITONAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LOPINAVIR; P16 PROTEASE, HUMAN IMMUNODEFICIENCY VIRUS 1; RITONAVIR;

ANTIVIRAL RESISTANCE; ARTICLE; BINDING AFFINITY; CLUSTER ANALYSIS; CONTROLLED STUDY; DNA MODIFICATION; DRUG RESISTANCE; DRUG TREATMENT FAILURE; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MOLECULAR MODEL; PREVALENCE; STRUCTURAL MODIFICATION; TREATMENT OUTCOME; VIRUS MUTATION; WILD TYPE; ADULT; FEMALE; GENE REPRESSION; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; MISSENSE MUTATION; VIROLOGY; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HIV PROTEASE; HIV-1; HUMANS; LOPINAVIR; MALE; MIDDLE AGED; MUTATION, MISSENSE; RITONAVIR; SUPPRESSION, GENETIC; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84888354788     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt173     Document Type: Article

References (20)

1. Travers SA, Clewley JP, Glynn JR et al. Timing and reconstruction of the most recent common ancestor of the subtype C clade of human immunodeficiency virus type 1. J Virol 2004; 78: 10501-6.
2. Triques K, Bourgeois A, Saragosti S et al. High diversity of HIV-1 subtype F strains in Central Africa. Virology 1999; 259: 99-109.
3. Bello G, Guimarães ML, Chequer-Fernandez SL et al. Increasing genetic distance to HIV-1 subtype B and F1 consensus sequences in the Brazilian epidemic: a challenge for vaccine strategies based on central immunogens? Infect Genet Evol 2007; 7: 594-9.
4. Los Alamos National Laboratory Database. http://www.hiv.lanl.gov/content/sequence/HIV/COMPENDIUM/compendium.html (15 January 2013, date last accessed).
5. Clavel F, Hance AJ. HIVdrug resistance.NEngl JMed2004;350: 1023-35.
6. KimR, Baxter JD. Protease inhibitor resistanceupdate:wherearewenow? AIDS Patient Care STDS 2008; 22: 267-77.
7. Ceccherini-Silberstein F, Erba F, Gago F et al. Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure. AIDS 2004; 18: F11-9.
8. Bennett DE, Camacho RJ, Otelea D et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009; 4: e4724.
9. Theys K, Deforche K, Vercauteren J et al. Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients. Retrovirology 2012; 9: 81.
10. Johnson VA, Calvez V, Günthard FH et al. Update of the drug resistance mutations in HIV-1: 2011. Top HIV Med 2011; 19: 4.
11. Sayer JM, Liu F, Ishima Ret al. Effect of the active-siteD25Nmutation on the structure, stability and ligand binding of the mature HIV-1 protease. J Biol Chem 2008; 283: 13459-70.
12. Perno CF, Cozzi-Lepri A, Balotta C et al. Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy. J Infect Dis 2001; 184: 983-91.
13. Perno CF, Cozzi-Lepri A, Forbici Fet al. Minormutations in HIV protease at baseline and appearance of primary mutation 90M in patients for whom their first protease-inhibitor antiretroviral regimens failed. J Infect Dis 2004; 189: 1983-7.
14. Scherrer AU, Ledergerber B, von Wyl V et al. Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients. PLoS One 2012; 7: e37983.
15. Svicher V, Ceccherini-Silberstein F, Erba F et al. Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors. Antimicrob Agents Chemother 2005; 49: 2015-25.
16. Kempf DJ, Isaacson JD, King MS et al. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J Virol 2001; 75: 7462-9.
17. Marcelin AG, Dalban C, Peytavin G et al. Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type-1 protease inhibitor-experienced patients. Antimicrob Agents Chemother 2004; 48: 4687-92.
18. Masquelier B, Breilh D, Neau D et al. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients. Antimicrob Agents Chemother 2002; 46: 2926-32.
19. Wang W, Kollman PA. Computational study of protein specificity: the molecular basis of HIV-1 protease drug resistance. Proc Natl Acad Sci USA 2001; 98: 14937-42.
20. Flor-Parra F, Pérez-Pulido AJ, PachónJet al. The HIV type1 protease L10I minor mutation decreases replication capacity and confers resistance to protease inhibitors. AIDS Res Hum Retroviruses 2011; 27: 65-70.